Clareo Health | Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy
Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant with T2DM on stable non-insulin antidiabetic therapy in addition to diet and exercise
Body mass index (BMI) ≥ 25 kg/m\^2 and ≤ 40 kg/m\^2
HbA1c 7 - 11%
Ability and willingness to maintain a complete and accurate Subject Activity Log during the course of the trial
Female of child-bearing potential must have agreed to use effective methods of contraception
Ability to understand and willing to sign written informed consent
You may not be if
Type 1 Diabetes Mellitus (T1DM)
T2DM with history of or current insulin therapy. Prior use during pregnancy or gestational diabetes was acceptable.
History of ketoacidosis or ketosis-prone diabetes
Clinically significant complications of diabetes that in the judgment of the investigator would have made participant unsuitable to participate in this trial
History of a severe episode of hypoglycemia
Change in non-insulin antidiabetic therapy in addition to diet and exercise \< 2 months prior to screening
Any clinically significant cardiovascular event \< 2 months prior to screening
Clinically significant, inadequately controlled or unstable hypertension
Hospitalization \< 2 months prior to screening
Major surgery \< 3 months prior to screening
Weight loss medication (prescription or non-prescription) \< 2 months prior to screening
